Table 1 Patient characteristics–primary tumours

From: Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT)

Category Subcategory HCC (n = 422) ICC (n = 120) All (n = 542)
ECOG status 0–fully active 252 (59.7%) 65 (54.2%) 317 (58.5%)
1–restricted 136 (32.2%) 41 (34.2%) 177 (32.7%)
2 or higher 34 (8.1%) 11 (9.2%) 45 (8.3%)
Missingb 3 (2.5%) 3 (0.6%)
Extra-hepatic disease No 382 (90.5%) 84 (70.0%) 466 (86.0%)
Yes 40 (9.5%) 36 (30.0%) 76 (14.0%)
Ascites No 357 (84.6%) 107 (89.2%) 464 (85.7%)
Yes 65 (15.4%) 13 (10.8%) 78 (14.3%)
Cirrhosis No 122 (28.9%) 105 (87.5%) 227 (41.9%)
Yes 300 (71.1%) 15 (12.5%) 315 (58.1%)
Location of liver tumours Bilobar 159 (37.7%) 71 (59.2%) 230 (42.4%)
Left only 51 (12.1%) 16 (13.3%) 67 (12.4%)
Right only 212 (50.2%) 33 (27.5%) 245 (45.2%)
Number of liver tumours 1 110 (26.1%) 32 (26.7%) 142 (26.2%)
2–5 154 (36.5%) 35 (29.2%) 189 (34.9%)
6–9 23 (5.5%) 10 (8.3%) 33 (6.1%)
10 or more 55 (13.0%) 10 (8.3%) 65 (12.0%)
Uncountable 80 (19.0%) 33 (27.5%) 113 (20.8%)
Portal vein Patent 282 (66.8%) 95 (79.2%) 377 (69.6%)
Segmental thrombosis 82 (19.4%) 14 (11.7%) 96 (17.8%)
Lobar thrombosis 38 (9.0%) 7 (5.8%) 45 (8.3%)
Main thrombosis 20 (4.7%) 4 (3.3%) 24 (4.4%)
Total tumour to liver percentage Median 9.2% 12.8% 10.0%
Q1, Q3 3.4%, 20.2% 7.9%, 21.5% 4.4%, 20.4%
Missing 67 (15.9%) 23 (19.2%) 90 (16.7%)